The post Trump reaches drug pricing deal with AstraZeneca appeared on BitcoinEthereumNews.com. U.S. President Donald Trump participates in a bilateral meeting with Finland’s President Alexander Stubb (not pictured), in the Oval office at the White House in Washington, D.C., U.S., Oct. 9, 2025. Nathan Howard | Reuters The Trump administration and AstraZeneca have reached an agreement for the U.K.-based pharmaceutical giant to cut drug prices in the U.S., MSNBC reported Friday. The deal with AstraZeneca would follow a similar pact with U.S. drugmaker Pfizer, which was announced late last month. President Donald Trump and AstraZeneca CEO Pascal Soriot will announce the agreement during a White House event on Friday, MSNBC reported, citing a White House official. AstraZeneca will agree to sell drugs directly to Medicaid patients at the lowest price offered in other developed countries, or what Trump calls “most-favored nation” pricing, on a coming government website called TrumpRx.gov, according to MSNBC. Pfizer agreed to similar terms with the Trump administration and received a three-year exemption from pharmaceutical sector tariffs as part of the agreement, on the condition that it continued to invest in U.S. manufacturing. It is unclear if the deal with AstraZeneca would also include such a carveout. AstraZeneca in July said it would invest $50 billion in the U.S. by 2030. The company announced further details about those plans Friday ahead of the reported pricing deal announcement. Trump has pushed drugmakers to cut prices and build out manufacturing in the U.S., as sky-high costs for medicines relative to other developed countries irk voters across the political spectrum. As his administration threatened pharmaceutical companies with tariffs as high as 250% in recent months, many drugmakers announced significant investments in the U.S. Trump has said he aims to strike pricing deals with other major drugmakers in the weeks ahead. “If we don’t make a deal, we’re going to tariff them,” he… The post Trump reaches drug pricing deal with AstraZeneca appeared on BitcoinEthereumNews.com. U.S. President Donald Trump participates in a bilateral meeting with Finland’s President Alexander Stubb (not pictured), in the Oval office at the White House in Washington, D.C., U.S., Oct. 9, 2025. Nathan Howard | Reuters The Trump administration and AstraZeneca have reached an agreement for the U.K.-based pharmaceutical giant to cut drug prices in the U.S., MSNBC reported Friday. The deal with AstraZeneca would follow a similar pact with U.S. drugmaker Pfizer, which was announced late last month. President Donald Trump and AstraZeneca CEO Pascal Soriot will announce the agreement during a White House event on Friday, MSNBC reported, citing a White House official. AstraZeneca will agree to sell drugs directly to Medicaid patients at the lowest price offered in other developed countries, or what Trump calls “most-favored nation” pricing, on a coming government website called TrumpRx.gov, according to MSNBC. Pfizer agreed to similar terms with the Trump administration and received a three-year exemption from pharmaceutical sector tariffs as part of the agreement, on the condition that it continued to invest in U.S. manufacturing. It is unclear if the deal with AstraZeneca would also include such a carveout. AstraZeneca in July said it would invest $50 billion in the U.S. by 2030. The company announced further details about those plans Friday ahead of the reported pricing deal announcement. Trump has pushed drugmakers to cut prices and build out manufacturing in the U.S., as sky-high costs for medicines relative to other developed countries irk voters across the political spectrum. As his administration threatened pharmaceutical companies with tariffs as high as 250% in recent months, many drugmakers announced significant investments in the U.S. Trump has said he aims to strike pricing deals with other major drugmakers in the weeks ahead. “If we don’t make a deal, we’re going to tariff them,” he…

Trump reaches drug pricing deal with AstraZeneca

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

U.S. President Donald Trump participates in a bilateral meeting with Finland’s President Alexander Stubb (not pictured), in the Oval office at the White House in Washington, D.C., U.S., Oct. 9, 2025.

Nathan Howard | Reuters

The Trump administration and AstraZeneca have reached an agreement for the U.K.-based pharmaceutical giant to cut drug prices in the U.S., MSNBC reported Friday.

The deal with AstraZeneca would follow a similar pact with U.S. drugmaker Pfizer, which was announced late last month.

President Donald Trump and AstraZeneca CEO Pascal Soriot will announce the agreement during a White House event on Friday, MSNBC reported, citing a White House official. AstraZeneca will agree to sell drugs directly to Medicaid patients at the lowest price offered in other developed countries, or what Trump calls “most-favored nation” pricing, on a coming government website called TrumpRx.gov, according to MSNBC.

Pfizer agreed to similar terms with the Trump administration and received a three-year exemption from pharmaceutical sector tariffs as part of the agreement, on the condition that it continued to invest in U.S. manufacturing.

It is unclear if the deal with AstraZeneca would also include such a carveout.

AstraZeneca in July said it would invest $50 billion in the U.S. by 2030. The company announced further details about those plans Friday ahead of the reported pricing deal announcement.

Trump has pushed drugmakers to cut prices and build out manufacturing in the U.S., as sky-high costs for medicines relative to other developed countries irk voters across the political spectrum. As his administration threatened pharmaceutical companies with tariffs as high as 250% in recent months, many drugmakers announced significant investments in the U.S.

Trump has said he aims to strike pricing deals with other major drugmakers in the weeks ahead.

“If we don’t make a deal, we’re going to tariff them,” he said late last month as he announced the Pfizer agreement.

This story is developing. Please check back for updates.

Source: https://www.cnbc.com/2025/10/10/trump-astrazeneca-drug-pricing-deal.html

Market Opportunity
OFFICIAL TRUMP Logo
OFFICIAL TRUMP Price(TRUMP)
$3.037
$3.037$3.037
+0.29%
USD
OFFICIAL TRUMP (TRUMP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Kalshi debuts ecosystem hub with Solana and Base

Kalshi debuts ecosystem hub with Solana and Base

The post Kalshi debuts ecosystem hub with Solana and Base appeared on BitcoinEthereumNews.com. Kalshi, the US-regulated prediction market exchange, rolled out a new program on Wednesday called KalshiEco Hub. The initiative, developed in partnership with Solana and Coinbase-backed Base, is designed to attract builders, traders, and content creators to a growing ecosystem around prediction markets. By combining its regulatory footing with crypto-native infrastructure, Kalshi said it is aiming to become a bridge between traditional finance and onchain innovation. The hub offers grants, technical assistance, and marketing support to selected projects. Kalshi also announced that it will support native deposits of Solana’s SOL token and USDC stablecoin, making it easier for users already active in crypto to participate directly. Early collaborators include Kalshinomics, a dashboard for market analytics, and Verso, which is building professional-grade tools for market discovery and execution. Other partners, such as Caddy, are exploring ways to expand retail-facing trading experiences. Kalshi’s move to embrace blockchain partnerships comes at a time when prediction markets are drawing fresh attention for their ability to capture sentiment around elections, economic policy, and cultural events. Competitor Polymarket recently acquired QCEX — a derivatives exchange with a CFTC license — to pave its way back into US operations under regulatory compliance. At the same time, platforms like PredictIt continue to push for a clearer regulatory footing. The legal terrain remains complex, with some states issuing cease-and-desist orders over whether these event contracts count as gambling, not finance. This is a developing story. This article was generated with the assistance of AI and reviewed by editor Jeffrey Albus before publication. Get the news in your inbox. Explore Blockworks newsletters: Source: https://blockworks.co/news/kalshi-ecosystem-hub-solana-base
Share
BitcoinEthereumNews2025/09/18 04:40
Urgent Warning For US Banks To Avoid Payments Market Collapse

Urgent Warning For US Banks To Avoid Payments Market Collapse

The post Urgent Warning For US Banks To Avoid Payments Market Collapse appeared on BitcoinEthereumNews.com. Crypto Regulatory Clarity: Urgent Warning For US Banks
Share
BitcoinEthereumNews2026/03/09 12:02
Trump’s Decisive Stance: US Will Consult Israel on Ending Iran War But Retains Final Authority

Trump’s Decisive Stance: US Will Consult Israel on Ending Iran War But Retains Final Authority

BitcoinWorld Trump’s Decisive Stance: US Will Consult Israel on Ending Iran War But Retains Final Authority WASHINGTON, D.C., March 2025 – In a significant statement
Share
bitcoinworld2026/03/09 12:40